Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPI Checkmate Pharmaceuticals	$10.50	$10.46	$2.00 ▼ $10.50	$231.40M	-4.81	142,261 shs	N/A
IOVA Iovance Biotherapeutics	$2.24 -3.0%	$2.55	$1.64 ▼ $12.51	$748.01M	0.86	8.92 million shs	8.78 million shs
LENZ LENZ Therapeutics	$29.00 -2.0%	$26.94	$16.28 ▼ $38.93	$816.23M	0.42	190,874 shs	156,488 shs
REPL Replimune Group	$9.78 -1.1%	$8.60	$6.44 ▼ $17.00	$753.91M	0.63	901,349 shs	680,187 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPI Checkmate Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
IOVA Iovance Biotherapeutics	0.00%	+9.27%	+27.27%	-37.60%	-73.74%
LENZ LENZ Therapeutics	0.00%	-9.26%	+6.07%	+13.95%	+55.00%
REPL Replimune Group	0.00%	-5.78%	+35.27%	-16.05%	+10.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPI Checkmate Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	4.6339 of 5 stars	4.3	1.0	0.0	4.2	2.2	4.2	1.3
LENZ LENZ Therapeutics	1.6484 of 5 stars	3.6	1.0	0.0	0.0	2.8	0.8	0.0
REPL Replimune Group	4.5225 of 5 stars	3.6	3.0	0.0	4.5	3.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPI Checkmate Pharmaceuticals	0.00	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$13.30	493.75% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	60.69% Upside
REPL Replimune Group	3.14	Buy	$20.83	113.02% Upside

Current Analyst Ratings Breakdown

Latest CMPI, IOVA, LENZ, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $20.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPI Checkmate Pharmaceuticals	N/A	N/A	N/A	N/A	$2.50 per share	N/A
IOVA Iovance Biotherapeutics	$212.68M	3.52	N/A	N/A	$2.28 per share	0.98
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$22.06 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$6.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPI Checkmate Pharmaceuticals	-$61.40M	-$2.92	N/A	N/A	N/A	N/A	-83.92%	-74.99%	N/A
IOVA Iovance Biotherapeutics	-$444.04M	-$1.24	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	8/6/2025 (Estimated)
LENZ LENZ Therapeutics	-$124.65M	-$1.77	N/A	N/A	N/A	N/A	-58.48%	-55.50%	8/13/2025 (Estimated)
REPL Replimune Group	-$215.79M	-$3.07	N/A	N/A	N/A	N/A	-54.84%	-42.97%	8/6/2025 (Estimated)

Latest CMPI, IOVA, LENZ, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
3/19/2025	Q4 2024	LENZ LENZ Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPI Checkmate Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPI Checkmate Pharmaceuticals	N/A	5.20	5.20
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
LENZ LENZ Therapeutics	N/A	28.63	28.63
REPL Replimune Group	0.14	11.43	11.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPI Checkmate Pharmaceuticals	74.56%
IOVA Iovance Biotherapeutics	77.03%
LENZ LENZ Therapeutics	54.32%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
CMPI Checkmate Pharmaceuticals	62.60%
IOVA Iovance Biotherapeutics	10.30%
LENZ LENZ Therapeutics	6.90%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPI Checkmate Pharmaceuticals	28	22.04 million	8.24 million	Not Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	267.90 million	Optionable
LENZ LENZ Therapeutics	110	28.15 million	16.94 million	N/A
REPL Replimune Group	210	77.09 million	70.24 million	Optionable

CMPI, IOVA, LENZ, and REPL Headlines

Recent News About These Companies

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE

June 14 at 3:10 AM | marketbeat.com

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan

June 6, 2025 | quiverquant.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Wellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)

June 3, 2025 | marketbeat.com

Piper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

June 2, 2025 | marketbeat.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2025 | globenewswire.com

Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

June 1, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

June 1, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?

May 31, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's Why

May 30, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC

May 30, 2025 | marketbeat.com

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

HC Wainwright Estimates Replimune Group Q3 Earnings

May 27, 2025 | marketbeat.com

Leerink Partnrs Estimates Replimune Group Q1 Earnings

May 27, 2025 | marketbeat.com

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review

May 26, 2025 | investing.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LP

May 25, 2025 | marketbeat.com

Millennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)

May 25, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Here's Why

May 24, 2025 | marketbeat.com

Traders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)

May 24, 2025 | marketbeat.com

Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings

May 24, 2025 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPI, IOVA, LENZ, and REPL Company Descriptions

Checkmate Pharmaceuticals NASDAQ:CMPI

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Iovance Biotherapeutics NASDAQ:IOVA

$2.24 -0.07 (-3.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.24 -0.01 (-0.22%)

As of 06/13/2025 07:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

LENZ Therapeutics NASDAQ:LENZ

$29.00 -0.58 (-1.96%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$29.08 +0.08 (+0.28%)

As of 06/13/2025 07:54 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Replimune Group NASDAQ:REPL

$9.78 -0.11 (-1.11%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.88 +0.10 (+0.97%)

As of 06/13/2025 07:38 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time